AMNOG impressively demonstrates its effectiveness

Fri, 2019 / 11 / 15
According to a study by the information provider IQVIA, due to the Drug Brand Reorganization Act (AMNOG) even greater savings can be expected this year than in the previous years.

AMNOG came into force on the 1st of January 2011 in order to reduce the rapidly rising costs of innovative drugs for health insurance companies and to ensure healthy competition between the researching pharmaceutical companies. The aim was to strike a new balance between innovation and affordability and to save a total of two billion euros per year. This goal has been fully achieved by AMNOG in 2018.

According to the study, the savings from reimbursements rose to a record high of 1.455 billion euros in the first half of 2019. The three-billion-euro-mark is therefore within sight for the entire year. If this were achieved, the savings would increase by 700 million euros compared to 2018 and even double compared to 2017 (1.57 billion euros).

In this context, 60% of the savings (1.4 billion euros) are caused by only five drug categories, including antineoplastic protease inhibitors, multiple sclerosis drugs and antidiabetics. Although they account for only 3% of the total drugs sold to SHI patients, they accounted for 22% of the total sales of all drugs that underwent the AMNOG procedure (August 2018 - July 2019). Another major cost item were biopharmaceuticals with 28% of the total sales and 9% of the total drugs sold.

With the help of the strategic support of SKC consulting, numerous extremely innovative drugs have already mastered AMNOG market access. As experts, we support our clients primarily in the areas of value dossier, market intelligence, strategic pricing and stakeholder management.

By Prof. Matthias P. Schönermark, M.D., Ph.D. and Sebastian Marben

Sources (German only):
Ärztezeitung.de: AMNOG Rabatte stark gestiegen
Pharmazeutische Zeitung: Das AMNOG wirkt
Statista: Arzneimittelausgaben GKV seit 1999

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
to the top